Measures

Phases 1 and 2 measures will involve using qualitative interview guides, informed by the extant literature and developed by the team, to identify important themes in the data. For phase 3, participants will complete the study assessment at enrollment (baseline) and at a 6-month follow-up, which will be digitally administered using iPads. The assessment will include self-report questions about HIV testing history, date(s) of previous testing, source(s) of previous testing, viral load, CD4 count, linkage and retention in care, TasP uptake, HIV medication, adherence and viral load if HIV-positive, and consideration of PrEP, including barriers and facilitators and its uptake, if HIV-negative. The assessment will also include measures that we will develop from the focus group data to assess participants’ knowledge, attitudes, and behavioral intentions toward TasP and PrEP use. Validated measures will include event-level characteristics of sexual risk episodes over the past 3 months, using the timeline follow-back interview method, with information on sexual activities, relationship with partner(s), partner gender, use of alcohol or drugs prior to or during, and use of condoms for each episode. Phase 3 will also involve fidelity monitoring of participants’ use of the intervention, including information about when they check or receive messages, whether they reply to messages or input information via messages, and whether they log calls to study staff.